Pharmacists To Get New Substitution Powers To Tackle Brexit Shortage Risk
In an effort to address possible serious drug shortages in the event of a no-deal Brexit, the UK government has formally proposed giving pharmacists wide powers to dispense alternative medicines such as different forms, generics, biosimilars, or “therapeutically equivalent” drugs.
You may also be interested in...
A public health advocacy group in the EU has issued tangible recommendations to address the perennial problem of drug shortages in the region.
UK pharmacists can now dispense a different medicine from the one prescribed, even if it contains a different active ingredient, under new laws on “serious shortage protocols” that came into force on 1 July as part of the government’s “no-deal Brexit” preparations.
Regulations that would allow the UK MHRA to work as a standalone regulator in the event of a no-deal Brexit have been laid before parliament. They cover a host of areas including new drug approval procedures, conversion of existing EU marketing authorizations into UK ones, pediatric and orphan exclusivities, imported medicines, and regulatory fees.